<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101612146</journal-id>
<journal-id journal-id-type="pubmed-jr-id">41582</journal-id>
<journal-id journal-id-type="nlm-ta">J Genet Disord Genet Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">J Genet Disord Genet Rep</journal-id>
<journal-title-group>
<journal-title>Journal of genetic disorders &amp; genetic reports</journal-title>
</journal-title-group>
<issn pub-type="epub">2327-5790</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28232951</article-id>
<article-id pub-id-type="pmc">5319728</article-id>
<article-id pub-id-type="doi">10.4172/2327-5790.1000139</article-id>
<article-id pub-id-type="manuscript">NIHMS837880</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical and Molecular Assessment in a Female with Fragile X Syndrome and Tuberous Sclerosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yrigollen</surname>
<given-names>Carolyn M</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pacini</surname>
<given-names>Laura</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nobile</surname>
<given-names>Veronica</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lozano</surname>
<given-names>Reymundo</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Randi J.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bagni</surname>
<given-names>Claudia</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tassone</surname>
<given-names>Flora</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, USA</aff>
<aff id="A2"><label>2</label>Department of Biomedicine and Prevention, University of Rome Tor Vergata, Italy</aff>
<aff id="A3"><label>3</label>Department of Pediatrics, University of California, Davis, USA</aff>
<aff id="A4"><label>4</label>MIND Institute, University of California, Davis, USA</aff>
<aff id="A5"><label>5</label>VIB Center for the Biology of Disease and Center for Human Genetics, Leuven, Belgium</aff>
<aff id="A6"><label>6</label>Department of Fundamental Neuroscience, University of Lausanne, Lausanne, Switzerland</aff>
<aff id="A7"><label>7</label>Department of Biochemistry and Molecular Medicine, University of California, Davis, USA</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding author: Flora Tassone, Department of Biochemistry and Molecular Medicine and MIND Institute, University of California, Davis 2805 50th Street, Sacramento, CA 95817, USA, Tel: 916-703-0463; Fax: 916-703-0464; <email>ftassone@ucdavis.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>10</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>21</day>
<month>2</month>
<year>2017</year>
</pub-date>
<volume>5</volume>
<issue>3</issue>
<elocation-id>139</elocation-id>
<self-uri xlink:href="http://www.scitechnol.com/peer-review/clinical-and-molecular-assessment-in-a-female-with-fragile-x-syndrome-and-tuberous-sclerosis-loaT.php?article_id=5263"></self-uri>
<abstract>
<sec id="S1">
<title>Objective</title>
<p id="P1">Fragile X syndrome (FXS) and tuberous sclerosis (TSC) are genetic disorders that result in intellectual disability and an increased prevalence of autism spectrum disorders (ASD). While the clinical presentation of each disorder is distinct, the molecular causes are linked to a disruption in the mTORC1 (mammalian Target of Rapamycin Complex 1) and ERK1/2 (Extracellular signal-Regulated Kinase) signaling pathways.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P2">We assessed the clinical and molecular characteristics of an individual seen at the UC Davis MIND Institute with a diagnosis of FXS and TSC. Clinical evaluation of physical, behavioral, and cognitive impairments were performed. Additionally, total and phosphorylated proteins along the mTORC1 and ERK1/2 pathways were measured in primary fibroblast cell lines from the proband.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">In this case the phenotypic effects that result in a human with both FXS and TSC are shown to be severe. Changes in mTORC1 and ERK1/2 signaling proteins and global protein synthesis were not found to be noticeably different between four cohorts (typically developing, <italic>FMR1</italic> full mutation, <italic>FMR1</italic> full mutation and <italic>TSC1</italic> loss of function mutation, and <italic>TSC1</italic> loss of function mutation); however cohort sizes prevented stringent comparisons.</p>
</sec>
<sec id="S4">
<title>Conclusion</title>
<p id="P4">It has previously been suggested that disruption of the mTORC1 pathway was reciprocal in TSC and FXS double knock-out mouse models so that the regulation of these pathways were more similar to wild-type mice compared to mice harboring a <italic>Fmr1<sup>−/y</sup></italic> or <italic>Tsc2<sup>−/+</sup></italic> mutation alone. However, in this first reported case of a human with a diagnosis of both FXS and TSC, substantial clinical impairments, as a result of these two disorders were observed. Differences in the mTORC and ERK1/2 pathways were not clearly established when compared between individuals with either disorder, or both.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Fragile X syndrome</kwd>
<kwd>Tuberous sclerosis</kwd>
<kwd>mTORC1</kwd>
<kwd>ERK1/2</kwd>
<kwd>Protein synthesis</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>